Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Radiation Oncology
•
Genitourinary Cancers
How does your institution manage node positive bladder cancer in the era of EV + Pembro and how does the approach differ between N1 vs N2-3?
Related Questions
How do you approach ADT in patients with high-risk prostate cancer who have risk factors for VTE, such as Factor V Leiden?
How do you interpret recent large retrospective analyses comparing radical prostatectomy vs. radiation for prostate cancer?
How do you design pelvic lymph node treatment volumes for patients with tortuous or aberrant vascular anatomy?
How would you manage T3N0M0 sarcomatoid carcinoma of the prostate with adenosquamous differentiation s/p prostatectomy?
How do you sequence Pluvicto vs docetaxel in a fit, chemotherapy-naïve patient with high-volume PSMA-avid mCRPC progressing on an ARPI?
How do you manage PSA progression while a patient is on Xofigo or Pluvicto?
Would you add whole-pelvis radiation as MDT (metastasis-directed therapy) in a patient with 1 pelvic node and 2 osseous metastatic sites for castrate-resistant prostate cancer?
Does the possibility of future Lu-177–PSMA therapy change your current threshold to offer earlier metastasis-directed RT in oligometastatic prostate cancer?
Would you continue serial PSMA PET scans after 2 negative scans for patients with a persistently rising PSA post-RT?
What are your top takeaways in GU Cancers from ASCO 2025?
